Daré Bioscience, Inc. (DARE) Earnings Call Transcripts
Daré Bioscience, Inc.'s Latest Earnings Call - March 26, 2026
In the earnings call for the fiscal year ended December 31, 2025, Daré Bioscience, Inc. (DARE:US) highlighted significant advancements in its women's health product pipeline, particularly the upcoming launch of DARE to PLAY, a topical sildenafil cream for female arousal. Management indicated that revenue generation from DARE to PLAY is expected to commence in Q2 2026, alongside the anticipated launch of Flora Sync LF5, a vaginal probiotic. The company ended 2025 with approximately $24.7 million in cash and cash equivalents and reported a decrease in R&D expenses, emphasizing the impact of non-dilutive funding on their financials. Guidance for future revenue remains optimistic, with multiple product launches expected to diversify revenue streams in 2026 and beyond.
Reported metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents | $24.7 million (beat) |
| R&D Expenses | $5.5 million (beat) |
| Total Revenue Guidance | Expected in Q2 2026 (positive) |
| Non-Dilutive Funding | $19.4 million (positive) |
| SG&A Expenses | $8.8 million (beat) |
| Flora Sync LF5 Launch | Q2 2026 (positive) |
Guidance from management
Management expects to begin recording revenue from DARE to PLAY and Flora Sync LF5 in Q2 2026, with a multiproduct revenue profile anticipated to grow across 2026 and 2027.
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for DARE to PLAY, particularly with compounded alternatives. There were questions about how the company plans to differentiate its product in a crowded market and the effectiveness of its marketing strategies to ensure consumer adoption.
Main topics on the call
- DARE to PLAY Launch — DARE to PLAY, a topical arousal cream, is set to begin dispensing nationally in Q2 2026. Management stated, "Women are finding their way to the DARE Health Hub, working through the telehealth process and providers are al...
- Financial Positioning — Daré ended 2025 with $24.7 million in cash and equivalents, bolstered by $20.8 million from equity sales and $19.4 million in non-dilutive funding. This positions the company well for upcoming product launches and operat...
- R&D Expense Dynamics — Reported R&D expenses decreased to $5.5 million from $14.3 million in 2024, primarily due to increased non-dilutive funding which offset reported costs. Management noted, "We are investing more in R&D than our reported R...
- Pipeline Expansion — The company is advancing multiple products, including DARE to RESTORE and DARE to RECLAIM, with Flora Sync LF5 expected to launch in Q2 2026. Management emphasized, "We have the most robust development stage pipeline of ...
Read the full Daré Bioscience, Inc. transcript (March 26, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Daré Bioscience, Inc.
Daré Bioscience, Inc. (DARE) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 35 calls on record spanning January 22, 2020 to August 11, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 35 Daré Bioscience, Inc. earnings call transcripts on record, spanning January 22, 2020 to August 11, 2026. Based on this history, Daré Bioscience, Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- DARE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 35
- First call
- January 22, 2020
- Most recent
- August 11, 2026
- Reporting cadence
- quarterly